Are Second- and Third-Line Treatments in the Elderly Feasible?

摘要: Currently, pemetrexed, docetaxel, erlotinib, and gefitinib have to be considered the standard treatment for patients with pretreated advanced NSCLC. Given similar efficacies of three currently available agents, patient’s preference, comorbidities, convenience are important issues consider when selecting a therapeutic agent. Although these considerations come from trials performed in general population, it is reasonable use them choice second- third-line therapy elderly as well. Unfortunately, second-line studies still lacking patients, but large amount new agents which investigating NSCLC may help increasing knowledge this specific setting.